Tyrosine kinase inhibitorFDA-approvedFirst-line
Encorafenib
How it works
Blocks the BRAF V600E mutation, a genetic abnormality that drives cancer cell growth, allowing the cancer cells to die.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median progression-free survival of approximately 9.2 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Encorafenib Plus Binimetinib for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Cost-effectiveness of cancer treatment in China questioned | Colorectal Cancer | phase-3 | — | Source → |
| Testing Binimetinib and Encorafenib for Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Study of Encorafenib and Binimetinib in Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Advanced Melanoma Treatment Trial Evaluates Combination of Three Study Medicines | Melanoma | phase-3 | — | Source → |
| Study of Combination Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| New Treatment Option for Chinese Patients with Aggressive Colorectal Cancer | Colorectal Cancer | phase-2 | The Doublet arm demonstrated superior progression-free survival of 4.2 months vs. 2.5 months in the Control arm. | Source → |
| Study of Encorafenib and Binimetinib for BRAF Mutant Melanoma with Brain Metastasis | Melanoma | phase-2 | Treatment with encorafenib plus binimetinib demonstrated a brain metastasis response rate of over 60%. | Source → |
| New Treatment Option for Lung Cancer Patients with V600E Mutation | Lung Cancer | phase-2 | Encorafenib plus binimetinib achieved the primary endpoint of objective response rate by independent review committee. | Source → |
| Rare Cancer Complication Found in Patient with BRAF Mutated Colon Cancer | Colorectal Cancer | observational | — | Source → |
| Encorafenib Interactions with Other Medications | Melanoma | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.